What we are researching
The purpose of this study is to evaluate how the study medicine is tolerated by people, who live with obesity and do not tolerate GLP-1-RA therapies due to gastrointestinal (GI) adverse effects.
Who may participate
Each clinical trial has its own requirements for who can participate, often called eligibility criteria. Some of the key criteria for this study are listed here. Discuss these requirements with your study doctor to determine if you may be eligible to participate. Additional criteria for your doctor to review can be found here NCT07607587.
Overweight or Obesity
Have a body mass index (BMI) of 30 or higher
Previous Treatment
Previous treatment with a GLP-1-RA that you had to stop due to GI adverse effects
Type 1 or 2 Diabetes
Have not been diagnosed with type 1 or type 2 diabetes
Age
18+ years
Study Medicine
Once weekly injection
Number of study visits
About 11 visits over a period of about 8 months
What to expect
If your study doctor determines that you are eligible and you decide to participate, you will be enrolled into the study.
Once enrolled, you will be randomly assigned to receive either the study medicine or placebo (which has no active medicine in it). Both are given as injections under the skin, using an injection pen. Your study team will teach you how to use the injection pen.
Your participation is expected to last about 8 months, with in-person visits every 3 to 4 weeks. Visits may include physical exams, lab tests and questionnaires to monitor your health and safety.
Call 866-867-7178 or email clinicaltrials@novonordisk.com to learn more
about the study and find out whether there is a participating study site near you.
When you call, please reference study 8420
You may also choose to discuss this clinical trial with your healthcare provider.